SIRION Biotech opens new office in Massachusetts

CAMBRIDGE, Mass.–(BUSINESS WIRE)–SIRION Biotech International Inc., a wholly-owned subsidiary of SIRION Biotech GmbH in Germany (“SIRION”), offering the most comprehensive portfolio of custom viral vectors for preclinical and clinical studies, today announced the grand opening of a new office at 125 Cambridgepark Drive, Suite 301, Cambridge, Massachusetts 02140.

SIRION was pleased to meet its new neighbors last night when it hosted a Bavarian-themed grand opening event at the Forsyth Institute to meet and mingle with the Cambridge gene therapy scene.

World renowned gene cell therapy developers and viral vector experts talked about the importance of the right viral vectors in making gene therapy a reality.

Gene therapy has seen strong clinical advancement, and SIRION is becoming a partner of choice in this growing sector as demonstrated by recent deals with Denali Therapeutics, Orchard Therapeutics, and an additional, undisclosed alliance with a major public company that is advancing the discipline.

“As transduction and manufacturing efficiencies are critical issues in gene therapy, SIRION’s viral vectors are essential to the success of their partnering companies,” said Dieter Lingelbach, Chief Operating Officer of SIRION Biotech. Dieter continued, “Since two-thirds of SIRION’s revenue already comes from US customers and partners, opening an office in a Life Science hub like Cambridge, Massachusetts further demonstrates our commitment to supporting existing customers and further expanding into the US market.”

Related posts

• Dr. Henry’s Vitamins introduces Prenatal Plus and Omega-3 for Women (0)
• Ablynx wins Cablivi FDA approval for rare blood clotting disorder (0)
• Dr. Reddy’s appoints Marc Kikuchi as new head of generics business in North America (0)
• Spectrum offloads seven hematology/oncology drugs to Acrotech in $300m deal (0)
• FDA accepts X-Rx new drug application for IPD drug X-165 (0)
• Tamr joins Accenture’s life sciences ecosystem to help drive innovation in drug discovery and scientific research (0)
• Lilly to acquire Stamford biopharma company Loxo Oncology in $8bn deal (0)
• US biotech company Celgene to be acquired by Bristol-Myers Squibb for $74bn (0)
• Spectrum seeks ROLONTIS approval for chemotherapy-induced neutropenia (0)
• FDA accepts to review NDA of Kala’s dry eye drug KPI-121 0.25% (0)

The post SIRION Biotech opens new office in Massachusetts appeared first on PharmaNewsDaily.com.